Clinical Report: Investigational TKIs for Retinal Exudative Diseases

Overview

Vorolanib, axitinib, and migaldendranib are being investigated as novel therapies for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). These tyrosine kinase inhibitors (TKIs) may provide sustained treatment options that address the limitations of current anti-VEGF therapies.

Background

Retinal exudative diseases such as nAMD and DME present significant challenges in clinical management, primarily due to the limitations of existing anti-VEGF therapies. These therapies, while effective, often require frequent administration, leading to treatment burden and patient undertreatment. Investigational TKIs represent a promising avenue for enhancing treatment durability and reducing the frequency of interventions.

Data Highlights

Key Findings

• Vorolanib, axitinib, and migaldendranib function intracellularly to inhibit all three VEGFRs, differing from traditional anti-VEGF therapies.
• Vorolanib and axitinib also inhibit fibroblast growth factor receptors (FGFR) and platelet-derived growth factor receptor (PDGFR), expanding their therapeutic potential.
• Axitinib's inhibition of TIE2 may pose risks for vascular stability, potentially leading to increased vessel leakage.
• Oral administration of TKIs has shown poor tolerability, prompting a shift towards ocular delivery methods for sustained release.
• Clinical trials are ongoing to evaluate the efficacy and safety of these TKIs in reducing treatment burden while maintaining disease control.

Clinical Implications

The introduction of TKIs could significantly alter treatment paradigms for nAMD and DME by providing longer-lasting effects and reducing the frequency of required treatments. Clinicians should stay informed about ongoing trials and emerging data to better tailor treatment strategies for their patients.

Conclusion

Investigational TKIs offer a novel approach to managing retinal exudative diseases, potentially addressing unmet needs in treatment durability and patient compliance. Continued research will be essential to determine their role in clinical practice.

References

1. Retinal Physician, 2025 -- Tyrosine Kinase Inhibitors in Retinal Exudative Diseases
2. Retinal Physician, 2026 -- The Evolving TKI Pipeline
3. AAO Age-Related Macular Degeneration Guideline Summary - Guideline Central
4. Modern Retina, 2026 -- A review of the DAVIO 2 phase 2 trial results
5. retinal physician — The Evolving TKI Pipeline
6. Retinal Physician — The Evolving TKI Pipeline
7. AAO Age-Related Macular Degeneration Guideline Summary - Guideline Central
8. A review of the DAVIO 2 phase 2 trial results | Modern Retina
9. Axpaxli Superior to Aflibercept in Wet AMD Trial | Retinal Physician